Get the Stockscreener App
0.4608
10.68%
-0.0551
After Hours:
.49
0.0292
+6.34%
Unicycive Therapeutics Inc stock is traded at $0.4608, with a volume of 2.71M.
It is down -10.68% in the last 24 hours and down -18.31% over the past month.
See More
Previous Close:
$0.5159
Open:
$0.4772
24h Volume:
2.71M
Relative Volume:
2.57
Market Cap:
$53.55M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-0.2973
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
-19.85%
1M Performance:
-18.31%
6M Performance:
+27.26%
1Y Performance:
-67.55%
1-Day Range:
$0.45
$0.5099
1-Week Range:
$0.45
$0.64
52-Week Range:
$0.202
$1.45
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
0.4608 | 53.55M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - ACCESS Newswire
UNCY FY2025 EPS Lifted by Brookline Capital Management - Defense World
HC Wainwright Issues Pessimistic Estimate for UNCY Earnings - Defense World
Brookline Capital Management Weighs in on UNCY Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - Defense World
Unicycive stock target raised to $7.50 by H.C. Wainwright - Investing.com Canada
Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS - MarketBeat
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive Look: Unicycive Unveils Latest Kidney Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Unicycive Therapeutics, Inc. SEC 10-K Report - TradingView
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
FDA to Review Unicycive's Kidney Disease Drug in June 2025: Key Financial Updates - Stock Titan
Unicycive Approaches Its First Approval, But In A Competitive Space - insights.citeline.com
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday - Defense World
Unicycive to Highlight Patient Reported Outcomes Data at - GlobeNewswire
Revolutionary Dialysis Treatment Cuts Pill Burden in Half: Key Clinical Data Coming - StockTitan
Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News
Unicycive Therapeutics Inc (NASDAQ: UNCY) Is One Of The Hottest Stocks Right Now. - Stocks Register
Unicycive reports potential kidney disease treatment advance By Investing.com - Investing.com Nigeria
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 - The Manila Times
Unicycive reports potential kidney disease treatment advance - Investing.com
Unicycive Therapeutics Announces the Publication of - GlobeNewswire
Groundbreaking Kidney Disease Treatment Shows 41% Better ResultsCan This Change Dialysis Patient Care? - StockTitan
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 51.6% in January - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex
Investing in Unicycive Therapeutics Inc [UNCY]: What You Must Know - Knox Daily
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Is Expected To Breakeven In The Near Future - Simply Wall St
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Rises By 25.4% - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Gains Momentum, Closing at 0.61 - The Dwinnex
Unicycive Therapeutics' (UNCY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Unicycive highlights challenges in phosphate management - MSN
Unicycive Therapeutics Inc (UNCY) Has A Gold Mine On Its Hands - Stocks Register
Unicycive Therapeutics (NASDAQ:UNCY) Earns “Buy” Rating from HC Wainwright - Defense World
Unicycive Therapeutics Announces the Publication of Patient - GlobeNewswire
Unicycive highlights challenges in phosphate management By Investing.com - Investing.com Australia
Unicycive Therapeutics Publishes Review on Patient Perspectives in Phosphate Management for Chronic Kidney Disease - Nasdaq
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science - GlobeNewswire Inc.
Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation - Yahoo Finance
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update - MarketBeat
Unicycive Therapeutics’ (UNCY) Buy Rating Reiterated at HC Wainwright - Defense World
Unicycive Therapeutics Receives Notice of Non-Compliance from Nasdaq - Defense World
Unicycive Therapeutics (NASDAQ:UNCY) Receives "Buy" Rating from HC Wainwright - MarketBeat
Unicycive Therapeutics granted extension to meet Nasdaq compliance - Investing.com
Unicycive Therapeutics granted extension to meet Nasdaq compliance By Investing.com - Investing.com Canada
Unicycive reports positive phase 1 results for kidney drug By Investing.com - Investing.com Australia
Unicycive reports positive phase 1 results for kidney drug - Investing.com
Unicycive Therapeutics Announces Publication of Positive - GlobeNewswire
Unicycive's OLC Drug Shows Strong Safety Profile in Phase 1 Trial, FDA Decision Due 2025 - StockTitan
Unicycive Therapeutics Inc (NASDAQ: UNCY) Is A Safe Investment Now, Isn’t It? - Stocks Register
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):